NO951219L - Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav - Google Patents
Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling deravInfo
- Publication number
- NO951219L NO951219L NO951219A NO951219A NO951219L NO 951219 L NO951219 L NO 951219L NO 951219 A NO951219 A NO 951219A NO 951219 A NO951219 A NO 951219A NO 951219 L NO951219 L NO 951219L
- Authority
- NO
- Norway
- Prior art keywords
- plasminogen
- blood clots
- liposomes
- preparation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det omtales et farmasøytisk preparat for behandling av blodpropper såvel som et diagnostisk middel for på- visning av blodpropper. Preparatet omfatter et liposom eller en annen bionedbrytbar kolloidal bærer som har til seg bundet et plasminogen som et målsøkende stoff og om- fatter en plasminogenaktivator, og særlig en plasminogen- aktivator (tPA) av vevstypen, som blodproppoppløsende protein, eller et diagnostisk middel. Det omtales også en fremgangsmåte til fremstilling av et preparat med blodproppnedbrytende egenskaper, og fremgangsmåten innbefatter at plasminogen bindes til liposomer, idet plasminogenets affinitet overfor fibrin stort sett opprettholdes, og det inkorporeres en plas- minogenaktivator i liposomen under betingelser slik at samvirkningen mellom plasminogenet og plasminogenaktiva- toren nedsettes. Det omtales også en fremgangsmåte for å binde plas- minogen til liposomer idet et stort sett renset plasmino- gen anvendes som startmateriale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9201722A NL9201722A (nl) | 1992-10-05 | 1992-10-05 | Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan. |
PCT/NL1993/000195 WO1994007537A1 (en) | 1992-10-05 | 1993-10-05 | Pharmaceutical composition for site-specific release of a clot-dissolving protein |
Publications (2)
Publication Number | Publication Date |
---|---|
NO951219D0 NO951219D0 (no) | 1995-03-30 |
NO951219L true NO951219L (no) | 1995-06-06 |
Family
ID=19861342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO951219A NO951219L (no) | 1992-10-05 | 1995-03-30 | Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0662841B1 (no) |
JP (1) | JPH08502060A (no) |
AT (1) | ATE171073T1 (no) |
AU (1) | AU5345494A (no) |
CA (1) | CA2146324A1 (no) |
DE (1) | DE69321131D1 (no) |
NL (1) | NL9201722A (no) |
NO (1) | NO951219L (no) |
WO (1) | WO1994007537A1 (no) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
DE19529223A1 (de) * | 1995-08-09 | 1997-02-13 | Boehringer Mannheim Gmbh | Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE831867A (fr) * | 1975-07-29 | 1976-01-29 | Association d'un activateur du plasminogene, d'une part, et du plasminogene lui-meme | |
JPS52102975A (en) * | 1976-02-24 | 1977-08-29 | Toyota Motor Corp | Hydraulic driving system |
US4193983A (en) * | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
ZA869434B (en) * | 1985-12-16 | 1988-07-27 | Ethicon Inc | Method for inhibiting post-surgical adhesion formation by the topical administration of tussue plasminogen activator |
US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
-
1992
- 1992-10-05 NL NL9201722A patent/NL9201722A/nl not_active Application Discontinuation
-
1993
- 1993-10-05 DE DE69321131T patent/DE69321131D1/de not_active Expired - Lifetime
- 1993-10-05 EP EP93923685A patent/EP0662841B1/en not_active Expired - Lifetime
- 1993-10-05 CA CA002146324A patent/CA2146324A1/en not_active Abandoned
- 1993-10-05 AT AT93923685T patent/ATE171073T1/de active
- 1993-10-05 WO PCT/NL1993/000195 patent/WO1994007537A1/en active IP Right Grant
- 1993-10-05 JP JP6508918A patent/JPH08502060A/ja active Pending
- 1993-10-05 AU AU53454/94A patent/AU5345494A/en not_active Abandoned
-
1995
- 1995-03-30 NO NO951219A patent/NO951219L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0662841B1 (en) | 1998-09-16 |
JPH08502060A (ja) | 1996-03-05 |
CA2146324A1 (en) | 1994-04-14 |
NO951219D0 (no) | 1995-03-30 |
NL9201722A (nl) | 1994-05-02 |
DE69321131D1 (de) | 1998-10-22 |
EP0662841A1 (en) | 1995-07-19 |
ATE171073T1 (de) | 1998-10-15 |
WO1994007537A1 (en) | 1994-04-14 |
AU5345494A (en) | 1994-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5025868B2 (ja) | 可逆的に不活性な酸性化プラスミン組成物の調製法 | |
Björk et al. | The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. | |
Collen | Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent | |
DE69015182T2 (de) | Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. | |
DE69921102D1 (de) | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen | |
US7544500B2 (en) | Process for the production of a reversibly inactive acidified plasmin composition | |
JP2631645B2 (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
AU610104B2 (en) | Pharmaceutically active conjugates having improved body tissue binding specificity | |
HUT58812A (en) | Process for producing tissue plasminogen activator (t-pa) zimogenes and compositions containing them as active components | |
KR910700336A (ko) | 조작형 플라스미노겐 활성화제의 유도체 | |
AU2036188A (en) | New tissue plasminogen activator | |
ES2183805T3 (es) | Procedimiento de preparacion de un medicamento trombolitico. | |
EP0355068A3 (en) | Recombinant hybrid immunoglobulin molecules and their use | |
Bode et al. | Thrombolysis by a fibrin-specific antibody Fab′-urokinase conjugate | |
Thorsen et al. | Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator | |
US5747291A (en) | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect | |
Swenson et al. | α-Fibrinogenases | |
NO951219D0 (no) | Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav | |
RU2112528C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- ε(γ GLY)-LYS-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ | |
JPH0570607B2 (no) | ||
Bachmann | Fibrinolytic agents | |
Swenson et al. | Fibrolase | |
ES2033295T3 (es) | Un metodo para preparar un activador de plasminogeno. | |
Dewerchin et al. | Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin | |
Suzuki et al. | A study on the properties of commercial thrombin preparations |